260 related articles for article (PubMed ID: 18024406)
1. Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children.
Kager L; Lion T; Attarbaschi A; Koenig M; Strehl S; Haas OA; Dworzak MN; Schrappe M; Gadner H; Mann G;
Haematologica; 2007 Nov; 92(11):1561-4. PubMed ID: 18024406
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of t(1;19)/ TCF3-PBX1 in childhood acute lymphoblastic leukemia in the context of Berlin-Frankfurt-Münster-based protocols.
Felice MS; Gallego MS; Alonso CN; Alfaro EM; Guitter MR; Bernasconi AR; Rubio PL; Zubizarreta PA; Rossi JG
Leuk Lymphoma; 2011 Jul; 52(7):1215-21. PubMed ID: 21534874
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of genomic translocation breakpoints and identification of an alternative TCF3/PBX1 fusion transcript in t(1;19)(q23;p13)-positive acute lymphoblastic leukaemias.
Paulsson K; Jonson T; Ora I; Olofsson T; Panagopoulos I; Johansson B
Br J Haematol; 2007 Jul; 138(2):196-201. PubMed ID: 17593026
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and prognostic significance of TCF3-PBX1 fusion gene in Chinese children with acute lymphoblastic leukemia by using a modified ALL-BFM-95 protocol.
Pang L; Liang Y; Pan J; Wang JR; Chai YH; Zhao WL
Pediatr Hematol Oncol; 2015 Apr; 32(3):173-81. PubMed ID: 25551271
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
[TBL] [Abstract][Full Text] [Related]
7. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies.
Biondi A; Rizzari C; Valsecchi MG; De Lorenzo P; Aricò M; Basso G; Locatelli F; Lo Nigro L; De Rossi G; Masera G
Haematologica; 2006 Apr; 91(4):534-7. PubMed ID: 16537119
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
9. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
Holownia A; Trofimiuk E; Krawczuk-Rybak M; Jakubow P; Kaliszewski J; Muszynska-Roslan K; Braszko JJ
Acta Haematol; 2004; 112(4):222-4. PubMed ID: 15564737
[No Abstract] [Full Text] [Related]
11. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
Reismüller B; Attarbaschi A; Peters C; Dworzak MN; Pötschger U; Urban C; Fink FM; Meister B; Schmitt K; Dieckmann K; Henze G; Haas OA; Gadner H; Mann G;
Br J Haematol; 2009 Feb; 144(4):559-70. PubMed ID: 19077160
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary results of BFM 96 protocol in treatment of childhood ALL relapse in the experience of the Polish Paediatric Leukaemia /Lymphoma Study Group].
Chybicka A; Bogusławska-Jaworska J; Gorczyńska E; Armata J; Balcerska A; Balwierz W; Bubala H; Filiks-Litwin B; Kołecki P; Kowalczyk J; Łukowska K; Matysiak M; Rokicka-Milewska R; Rola-Kurc E; Stencel D; Sonta-Jakimczyk D; Strojny W; Wachowiak J; Wieczorek M; Wysocki M; Zelenay E
Med Wieku Rozwoj; 2000; 4(1 Suppl 2):43-8. PubMed ID: 12021461
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
Badowska W
Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
[TBL] [Abstract][Full Text] [Related]
15. Treatment of B-cell malignancies in children with a modified BFM-NHL 90 protocol in Argentina.
Chantada G; Casak S; Alderete D; Zubizarreta P; Gallo G; Muriel FS
Med Pediatr Oncol; 2003 Nov; 41(5):488-90. PubMed ID: 14515400
[No Abstract] [Full Text] [Related]
16. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
[TBL] [Abstract][Full Text] [Related]
17. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Pichler H; Reismüller B; Steiner M; Dworzak MN; Pötschger U; Urban C; Meister B; Schmitt K; Panzer-Grümayer R; Haas OA; Attarbaschi A; Mann G;
Br J Haematol; 2013 May; 161(4):556-65. PubMed ID: 23480776
[TBL] [Abstract][Full Text] [Related]
18. [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].
Derwich K; Wachowiaki J; Kaczmarek-Kanoldi M; Balcerska A; Balwierz W; Chybicka A; Kowalczyk JR; Matysiak M; Jackowska T; Sońta-Jakimczyk D; Wysocki M; Chełmecka-Hanuszewicz L; Cwiklińska M; Kołtan A; Malinowska I; Odój T; Płoszyńska A; Steczowicz M; Wojciechowska V; Wójtowicz A;
Przegl Lek; 2006; 63(1):7-10. PubMed ID: 16892891
[TBL] [Abstract][Full Text] [Related]
19. Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study.
Aricò M; Conter V; Valsecchi MG; Rizzari C; Boccalatte MF; Barisone E; Messina C; De Rossi G; Lo Nigro L; Pession A; Locatelli F; Micalizzi C; Basso G
Haematologica; 2005 Sep; 90(9):1186-91. PubMed ID: 16154841
[TBL] [Abstract][Full Text] [Related]
20. [Childhood acute lymphoblastic leukemia in Norway 1992-2000].
Kolmannskog S; Flaegstad T; Helgestad J; Hellebostad M; Zeller B; Glomstein A
Tidsskr Nor Laegeforen; 2007 May; 127(11):1493-5. PubMed ID: 17551551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
